BeOne Medicines (NASDAQ:ONC) CFO Aaron Rosenberg Sells 631 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CFO Aaron Rosenberg sold 631 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $257.74, for a total value of $162,633.94. Following the sale, the chief financial officer owned 397,891 shares in the company, valued at approximately $102,552,426.34. The trade was a 0.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Up 1.4%

ONC opened at $268.20 on Tuesday. The business’s fifty day moving average is $298.56 and its two-hundred day moving average is $314.03. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The company has a market cap of $29.43 billion, a price-to-earnings ratio of 60.00 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Hedge Funds Weigh In On BeOne Medicines

A number of institutional investors have recently made changes to their positions in the stock. Capital International Investors raised its holdings in shares of BeOne Medicines by 1.3% in the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock worth $1,553,909,000 after acquiring an additional 67,808 shares during the last quarter. Siren L.L.C. raised its holdings in shares of BeOne Medicines by 1.4% in the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock worth $151,905,000 after acquiring an additional 7,010 shares during the last quarter. Morgan Stanley raised its holdings in shares of BeOne Medicines by 23.9% in the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock worth $132,966,000 after acquiring an additional 84,367 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after acquiring an additional 26,441 shares during the last quarter. Finally, Candriam S.C.A. raised its holdings in shares of BeOne Medicines by 31.7% in the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock worth $77,132,000 after acquiring an additional 62,470 shares during the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on ONC. Wells Fargo & Company began coverage on BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 target price on the stock. Truist Financial reiterated a “buy” rating and set a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Zacks Research upgraded BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research report on Thursday, June 4th. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Barclays boosted their target price on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BeOne Medicines presently has an average rating of “Moderate Buy” and an average price target of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.